- Home
- / Indivior
Indivior
Revenue
$1.2 B
FY, 2025
Indivior Summary
Company Summary
- Overview
- Indivior is a pharmaceutical company focused on developing treatments for substance use disorders and mental health conditions. It specializes in treatments for opioid use disorder.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2014
- HQ
- Kingston upon Hull, GB | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ryan Preblick, Chief Financial Officer
Jeffrey Burris, Chief Legal Officer
Cynthia Cetani, Chief Integrity and Compliance Officer
Operating MetricsView all
Phase III Trials Products
4
FY, 2016
Clinical Programs
12
FY, 2016
Phase I Trials Products
4
FY, 2016
LocationsView all
1 location detected
Kingston upon Hull, England HQ
United Kingdom
Dansom Ln S
Indivior Financials
Summary Financials
- Revenue (FY, 2025)
- $1.2B
- Gross profit (FY, 2025)
- $1.0B
- Net income (FY, 2025)
- $210.0M
- Cash (FY, 2025)
- $195.0M
- EBIT (FY, 2025)
- $262.0M